Table 1.
Baseline Characteristics of the Cohort
| Characteristic | No.=566 | |
|---|---|---|
| Age, median (range) | 65 (23–98) | |
| Men, No. (%) | 397 (70.1) | |
| ECOG Performance Status of 0 or 1, No. (%) | 515a (92.5) | |
| Prior Treatments, median (range) | 3 (0–18) | |
| Malignancy Type | No. | % |
| Chronic lymphocytic leukemia | 417 | 73.7 |
| Mantle cell lymphoma | 56 | 9.9 |
| Diffuse Large B-cell Lymphomab | 35 | 6.2 |
| Follicular lymphoma | 15 | 2.7 |
| Hairy cell leukemia | 13 | 2.3 |
| Richter’s Syndromec | 12 | 2.1 |
| Waldenstrom’s macroglobulinemia | 11 | 1.9 |
| Marginal zone lymphoma | 6 | 1.1 |
| Prolymphocytic leukemia | 1 | 0.2 |
| Medical Comorbidities | No. | % |
| Hypertension | 248 | 43.8 |
| Diabetes | 71 | 12.5 |
| Chronic kidney disease | 68 | 12.0 |
| Pulmonary disease | 52 | 9.2 |
| Autoimmune disease | 22 | 3.9 |
| Liver disease | 15 | 2.7 |
| Human Immunodeficiency Virus (HIV) infection | 1 | 0.2 |
| Solid organ transplant | 1 | 0.2 |
| Antimicrobial Prophylaxis | No. | % |
| Viral | 445 | 78.6 |
| Valacyclovir | 290 | 51.2 |
| Acyclovir | 150 | 26.5 |
| Famciclovir | 3 | 0.5 |
| Valganciclovir | 2 | 0.4 |
| None | 121 | 21.4 |
| Pneumocystis jirovecii pneumonia | 254 | 44.9 |
| Bactrim | 221 | 39.0 |
| Dapsone | 26 | 4.6 |
| Atovaquone | 5 | 0.9 |
| Pentamidine | 2 | 0.4 |
| None | 312 | 55.1 |
| Fungal | 65 | 11.5 |
| Fluconazole | 46 | 8.1 |
| Voriconazole | 13 | 2.3 |
| Posaconazole | 3 | 0.5 |
| Caspofungin | 3 | 0.5 |
| None | 501 | 88.5 |
a
Out of 557 with available data.
b
Including transformed lymphomas
c
Any lymphoma in a patient with chronic lymphocytic leukemia
ECOG = Eastern Cooperative Oncology Group.